Gefitinib Intermediate CAS 199327-61-2 Purity >99.0% (HPLC)

7-Methoxy-6-(3-Morpholin-4-ylpropoxy)quinazolin-4(3H)-One (CAS: 199327-61-2) is an intermediate / impurity of Gefitinib (CAS: 184475-35-2). Gefitinib is a highly specific anti-tumor targeted therapeutic drug developed by AstraZeneca, UK. Gefitinib is the first molecular targeted drug for the treatment of non-small cell lung cancer.  It works by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK). In August 2002, Gefitinib was first marketed in Japan as a first-line treatment for non-small cell lung cancer under the trade name Iressa. In May 2003, the U.S. Food and Drug Administration approved Gefitinib as the third-line monotherapy for patients with advanced non-small cell lung cancer who were ineffective with platinum-based anticancer drugs and docetaxel chemotherapy. At present, Gefitinib has been approved by Australia, Japan, Argentina, Singapore and South Korea for the treatment of advanced non-small cell lung cancer. On February 28, 2005, the China Food and Drug Administration approved Gefitinib for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that had previously received chemotherapy.  It is not currently approved for use as first-line therapy for advanced NSCLC.  On July 1, 2009, the European Medicines Agency officially approved Gefitinib for the first-line, second-line and third-line treatment of locally advanced or metastatic non-small cell lung cancer with EGFR gene mutations in adults.